Artesunate 100mg + Mefloquine 220mg Tablet PCD Franchise in Ahmedabad

Antimalarial Tablet Supplier in Bangalore

Artesunate + Mefloquine Combination Distributor in Hyderabad

Malaria Treatment Tablet Franchise Opportunity in Jaipur

ACT Therapy Antimalarial Stockist in Mumbai
Artesunate Mefloquine Tablet Export and Manufacturing in Chandigarh

Home/Products /artesunate-100mg-mefloquine-220mg-tablet

About the Product

Description


Arteslide M Tablet contains Artesunate 100mg and Mefloquine 220mg, a WHO-recommended antimalarial combination for managing acute uncomplicated malaria. This dual therapy works rapidly to clear parasites from the bloodstream and deliver a sustained action to prevent recurrence. Artesunate acts quickly to reduce parasite load, while Mefloquine provides extended protection, making the combination highly effective in endemic regions.

The formulation is designed for improved absorption, consistent potency, and dependable therapeutic efficiency. Its effectiveness against resistant malaria strains makes it a preferred choice among healthcare professionals, especially in high-risk areas where recurrent malaria episodes are common. With strong clinical backing, this combination ensures faster recovery and reduced chances of treatment failure.

From a business perspective, Arteslide M Tablet offers massive demand in rural, semi-urban, and tropical regions where malaria cases peak seasonally. Antimalarials are a must-have category for every pharmacy, government tender supplier, and general medicine distributor, making this product a steady mover with assured year-round requirements.

Adding Arteslide M to your distribution line strengthens your presence in the infectious disease segment. It ensures consistent orders from clinics, hospitals, and healthcare centers while offering excellent growth potential through bulk supply, franchise distribution, third-party manufacturing, and export channels. This makes it a profitable and strategic product for expanding your antimalarial portfolio.

Some patients may experience nausea, vomiting, stomach discomfort, headache, dizziness, or fatigue. Mefloquine may rarely cause anxiety, mood changes, sleep disturbances, or vivid dreams. Serious allergic reactions or cardiac rhythm changes are uncommon but possible.

It is indicated for the treatment of acute uncomplicated malaria, particularly infections caused by Plasmodium falciparum. It helps reduce fever, chills, body pain, and other symptoms of malaria while supporting fast and sustained recovery.

Use strictly under medical supervision. Not recommended for patients with a history of psychiatric disorders, seizures, heart rhythm problems, or known hypersensitivity to either component. Complete the full prescribed course to prevent recurrence or resistance. Avoid alcohol during treatment.

Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Artesunate 100mg + Mefloquine 220mg Tablet in the PCD pharma franchise market?

This anti-malarial combination tablet has strong demand in the infectious disease and tropical healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on anti-infective and malaria care portfolios.

Why should medical distributors include this anti-malarial combination tablet in their product range?

Medical distributors and agencies can benefit from consistent demand for treatment and management of malaria and related parasitic infections, particularly in malaria-prone regions. Artesunate works rapidly to reduce malaria parasites in the bloodstream, while Mefloquine helps eliminate remaining parasites and reduce recurrence risk, strengthening a reliable anti-malarial product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this anti-malarial combination tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong demand in anti-malarial therapy, institutional and regional healthcare supply opportunities, reliable supply chain support, and good margins when partnering for this anti-infective product.

How can I become a distributor or franchise partner for this anti-malarial combination tablet?

Medical distributors, stockists, and wholesalers interested in this anti-malarial combination tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.